| Biological Information | |
|---|---|
| Background Information: | Serine/threonine protein kinases RSKs contain three isoforms RSK1, RSK2 and RSK3 and act at the distal end of MAPK Signaling pathway. They are directly phosphorylated and activated by ERK1/2 in response to many growth factors, peptide hormones and neurotransmitters. RSKs have been shown to regulate apoptosis through phosphorylation and inactivation of the pro-apoptotic protein BAD, and cell cycle since the kinase Myt1 is a RSK target. RSK3 (Ribosomal protein S6 kinase 3, SK6-alpha, MAPKAPK1C) is especially interesting, because it features an additional nuclear targeting signal near its N-terminus, and can phosphorylate a variety of transcription factors (CREB, TCF/Lef, Myc, the estrogen receptor, and the Fos subunit of AP-1).
GenBank XM_004469 |
| Target Class: | Kinase |
| Accession Number: | NM_001006932.1; NM_021135.4 |
| Target Name: | Rsk3 |
| Target Aliases: | RPS6KA2, S6K-alpha, RSK-3, MAPKAPK1C, RSK3, S6K-alpha2, pp90RSK3, HU-2, RSK, p90-RSK3 |
| Target Species: | Human |
| Usage | |
| Product Type: | Enzymes |
| Application: | Drug Discovery & Development |
| Storage Conditions: | 1 year at -70°C |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
Rsk3, active
N-terminal 6His-tagged recombinant, human full length RSK3.
Datasheets
14-462x Datasheet
View Document